|
|
Issue
|
Alert me when new journal issues are available via  or via  |
|
|
| Journal of Clinical Lipidology |
| Volume 4, Issue 3, Pages 139-236 (May-June 2010) |
|
Search Within This Issue
|
|
|
|
|
|
|
|
|
|
 =free full text
|
|
|
Editorial Board
pages iii-iv
Full-Text PDF (89 KB)
|
|
Table of Contents
pages vii-viii
Full-Text PDF (78 KB)
|
|
|
Foreword
|
|
From the Editor-in-Chief, 02 April 2010
W. Virgil Brown
pages 139-141
Full Text |
Full-Text PDF (83 KB)
|
|
News from the NLA, 22 March 2010
pages 142-143
Full Text |
Full-Text PDF (89 KB)
|
|
|
Clinical Lipidology Roundtable Discussion
|
|
Should we use apoB for risk assessment and as a target for treatment?†, 17 March 2010
W. Virgil Brown, Gary L. Myers, Allan D. Sniderman, Evan Stein
pages 144-151
Full Text |
Full-Text PDF (212 KB)
|
|
|
Review Articles
|
|
Why is non−high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?, 22 March 2010
Allan Sniderman, Matt McQueen, John Contois, Ken Williams, Curt D. Furberg
pages 152-155
Abstract |
Full Text |
Full-Text PDF (327 KB)
|
|
Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation, 17 March 2010
George S. Abela
pages 156-164
Abstract |
Full Text |
Full-Text PDF (947 KB)
|
|
|
Original Articles
|
|
Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: The Stop Atherosclerosis in Native Diabetics Study (SANDS), 08 February 2010
Charlton Wilson, Chun-Chih Huang, Nawar Shara, Barbara V. Howard, Jerome L. Fleg, Jeffrey A. Henderson, Wm. James Howard, Heather Huentelman, Elisa T. Lee, Mihriye Mete, Marie Russell, James M. Galloway, Angela Silverman, Mario Stylianou, Jason Umans, Matthew R. Weir, Fawn Yeh, Robert E. Ratner
pages 165-172
Abstract |
Full Text |
Full-Text PDF (142 KB)
|
|
Attainment of low-density lipoprotein cholesterol goals in coronary artery disease, 17 March 2010
Amy B. Kauffman, Kari L. Olson, Morgan L. Youngblood, Emily B. Zadvorny, Thomas Delate, John A. Merenich, Clinical Pharmacy Cardiac Risk Service Study Group
pages 173-180
Abstract |
Full Text |
Full-Text PDF (143 KB)
|
|
New mutations in APOB100 involved in familial hypobetalipoproteinemia, 03 March 2010
Klaus Brusgaard, Lars Kjaersgaard, Anne-Birthe Bo Hansen, Steffen Husby
pages 181-184
Abstract |
Full Text |
Full-Text PDF (218 KB)
|
|
Prevalence of metabolic syndrome and insulin resistance among Egyptian adolescents 10 to 18 years of age, 22 March 2010
Nebal A. Aboul Ella, Dina I. Shehab, Mervat A. Ismail, Awatif A. Maksoud
pages 185-195
Abstract |
Full Text |
Full-Text PDF (538 KB)
|
|
|
Letters to the Editor
|
|
Letter to the Editor, 04 March 2010
Douglas Trenkle
page 196
Full Text |
Full-Text PDF (74 KB)
|
|
Reply, 08 March 2010
David T. Nash
pages 196-197
Full Text |
Full-Text PDF (81 KB)
|
|
|
Abstracts
|
|
Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia
Andrew G. Bostom, Alexandra MacLean, Darbie Maccubbin, Diane Tipping, Hilde Gizek, William Hanlon
pages 198-199
Full Text |
Full-Text PDF (100 KB)
|
|
Efficacy and Selectivity of a Direct Absorption of Lipoproteins Apheresis System in Familial Hypercholesterolemic Omani Patients
Khalid Humaid Alrasadi, Ali Talib Al-Hinai
page 199
Full Text |
Full-Text PDF (38 KB)
|
|
A New Method to Evaluate the Hydrophility of Serum Lipoproteins
Gűnter Schrot
page 199
Full Text |
Full-Text PDF (38 KB)
|
|
Predicting the Risk of Atherothrombotic Disease with Lipid Ratios
William E. Feeman
pages 199-200
Full Text |
Full-Text PDF (49 KB)
|
|
Response by Sex to Statin and Ezetimibe Versus Statin Monotherapy: Pooled Analysis from 22,913 Hyperlipidemic Patients
Jennifer Robinson, Beth L. Abramson, Mary E. Hanson, Jianxin Lin, Arvind Shah, Andrew Tershakovec
page 200
Full Text |
Full-Text PDF (34 KB)
|
|
Achievement of Specified Lipid and High-Sensitivity C-Reactive Protein Levels with Statin-Ezetimibe Versus Statin in Male and Female Patients Using Combined Data from 22,913 Patients
Jennifer Robinson, Beth L. Abramson, Mary E. Hanson, Jianxin Lin, Arvind Shah, Andrew M. Tershakovec
pages 200-201
Full Text |
Full-Text PDF (50 KB)
|
|
Switching from Any Statin Brand to Ezetimibe/Simvastatin 10/20 mg is More Effective at Lowering Plasma Lipids Compared with Rosuvastatin 10 mg
Philippe Brudi, Maurizio Averna, Luc Missault, Michael Farnier, Helena Vaverkova, Margus Viigimaa, Qian Dong, Arvind Shah, William Taggart, Amy Johnson-Levonas
page 201
Full Text |
Full-Text PDF (46 KB)
|
|
Prevalence and Pattern of Dyslipidemia in Omani Patients Undergoing Coronary Artery Bypass Surgery
Hilal Al-Sabti, Khalid H. Al-Rasadi, Mirdavron M. Mukaddirov, Ali Talib Al-Hinai
pages 201-202
Full Text |
Full-Text PDF (56 KB)
|
|
Aging: The New Cholesterol
David T. Nash
page 202
Full Text |
Full-Text PDF (40 KB)
|
|
Rise in Plasma Triglycerides: An Early Marker of Oxidative Stress in Urban Indians
Sharmila Dudani, Shivani Kalhan, Suparna Dubey, Sonia Sharma, B.S. Raheja
pages 202-203
Full Text |
Full-Text PDF (50 KB)
|
|
BGS Graph Predicts Better Than the Framingham Risk Score
William E. Feeman
page 203
Full Text |
Full-Text PDF (37 KB)
|
|
The Role of Innate Inflammatory Mediators in Acute Myocardial Infarction∗
Joseph Thomas Poterucha, Scott W. Shurmur, Daniel R. Anderson
pages 203-204
Full Text |
Full-Text PDF (184 KB)
|
|
Blood Sugar Levels are Not Necessary to Predict the Population at Risk for Atherothrombotic Disease
William E. Feeman
page 204
Full Text |
Full-Text PDF (174 KB)
|
|
Efficacy of Switching from Statin Monotherapy to Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients Analyzed by Baseline LDL-C
Philippe Brudi, Maurizio Averna, Michael Farnier, Luc Missault, Helena Vaverkova, Margus Viigimaa, Qian Dong, Arvind Shah, William Taggart, Amy O. Johnson-Levonas
pages 204-205
Full Text |
Full-Text PDF (189 KB)
|
|
Switching from Statin Monotherapy to EZE/Simva or Rosuva Modifies Apo B, LDL-C, and non-HDL-C Correlations in Patients at High Risk of Coronary Disease
Philippe Brudi, Helena Vaverkova, Michael Farnier, Qian Dong, Amy O. Johnson-Levonas, Arvind Shah
page 205
Full Text |
Full-Text PDF (45 KB)
|
|
The Ability of Therapy with Ezetimibe/Simvastatin or Ezetimibe/Simvastatin/Fenofibrate to Achieve Lipid Targets in Mixed Dyslipidemic Patients
Michael Farnier, William Taggart, Jianxin Lin, Arvind Shah, Philippe Brudi
pages 205-206
Full Text |
Full-Text PDF (58 KB)
|
|
Improvements in Lipid Ratios with the Combination of Rosuvastatin 5 mg and Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia
Robert S. Rosenson, Maureen T. Kelly, Carolyn M. Setze, Alex Gold, Michael Cressman, James C. Stolzenbach, Laura A. Williams
page 206
Full Text |
Full-Text PDF (45 KB)
|
|
Simultaneous Achievement of Optimal Lipid Targets with the Combination of Rosuvastatin 5 mg + Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia
Robert S. Rosenson, Maureen T. Kelly, Carolyn M. Setze, Alex Gold, Michael Cressman, James C. Stolzenbach, Laura A. Williams
pages 206-207
Full Text |
Full-Text PDF (55 KB)
|
|
Stability of Lipid Responses to Prescription Omega-3 Acid Ethyl Esters Plus Simvastatin Over Two Years
Kevin Carl Maki, William S. Harris, Barry C. Lubin, Matthew S. Reeves, Mary R. Dicklin
page 207
Full Text |
Full-Text PDF (39 KB)
|
|
Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High Risk Hypercholesterolemic Patients Stratified by Previous Statin Treatment Potency
Michael Farnier, Margus Viigimaa, Helena Vaverkova, Maurizio Averna, Luc Missault, Qian Dong, Arvind Shah, Mary E. Hanson, Philippe Brudi
pages 207-208
Full Text |
Full-Text PDF (45 KB)
|
|
Clinical Pharmacist Services Significantly Increase Low-Density Lipoprotein Cholesterol Goal Attainment in an Outpatient-Based Lipid Clinic
Eric K. Gupta
page 208
Full Text |
Full-Text PDF (40 KB)
|
|
Effects of Vitamin D Supplementation on 25-Hydroxyvitamin D and Markers of Cardiovascular Disease Risk in Subjects with High Waist Circumference
Kevin Carl Maki, Martyn R. Rubin, Les G. Wong, Jamie F. McManus, Christopher D. Jensen, Rachel Hubacher, Andrea Lawless
pages 208-209
Full Text |
Full-Text PDF (51 KB)
|
|
Predictors of Anterior and Posterior Wall Carotid Intima Media Thickness Progression in Men and Women at Moderate Risk of Coronary Heart Disease
Kevin Carl Maki, Michael H. Davidson, Mary R. Dicklin, Marjorie Bell
page 209
Full Text |
Full-Text PDF (40 KB)
|
|
Omega-3 Fatty Acid Nutritional Labeling Content of Dietary Fish Oil Supplements: A Systematic Review∗
Atanaz Zargar, Matthew K. Ito
pages 209-210
Full Text |
Full-Text PDF (50 KB)
|
|
Atherogenic High-Density Lipoprotein in Subjects with Hyperalphalipoproteinemia
Catherine Janise McNeal, Craig Larner, Subroto Chatterjee, London Worthy, Ronald Macfarlane, Simon Sheather, Petar Alaupovic
page 210
Full Text |
Full-Text PDF (39 KB)
|
|
Long-Term Efficacy of Rosuvastatin and Fenofibric Acid 20 mg/135 mg in Dyslipidemic Patients Initially Treated with Rosuvastatin and Fenofibric Acid 10 mg/135 mg
Keith C. Ferdinand, Michael H. Davidson, Maureen T. Kelly, Carolyn M. Setze, Rick Schiebinger, Darryl J. Sleep
pages 210-211
Full Text |
Full-Text PDF (50 KB)
|
|
Effects of an Insoluble Fraction of Soy Protein Versus Milk Protein on Plasma Lipids and Fecal Bile Acids in Men and Women with Hypercholesterolemia
Kevin Carl Maki, Dustie N. Butteiger, Tia M. Rains, Matthew S. Reeves, Chuck Schasteen, Elaine S. Krul
page 211
Full Text |
Full-Text PDF (39 KB)
|
|
A Plant Sterol/Stanol Supplement in Tablet Form Lowers Low-Density Lipoprotein and Non-High-Density Lipoprotein Cholesterol in Men and Women with Primary Hypercholesterolemia
Kevin Carl Maki, Andrea Lawless, Matthew S. Reeves, Mary R. Dicklin, Belinda H. Jenks, Ed Shneyvas, James Brooks
pages 211-212
Full Text |
Full-Text PDF (49 KB)
|
|
A Variant of the LPA Gene Predicts Cardiovascular Event Reduction by Aspirin Therapy in a Primary Prevention Setting
Robert H. Superko, Dov Shiffman, James J. Devlin
page 212
Full Text |
Full-Text PDF (39 KB)
|
|
Adding Niacin Extended-Release (NER) to Simvastatin Improves Apolipoprotein B (apoB), apoA-I, the apoB:A-I Ratio, and Lipid Goal Attainment in the Highest-Risk Cardiometabolic Patients
Thao T. Doan, Ping Jiang, Roopal B. Thakkar, Moti L. Kashyap, Michael H. Davidson
pages 212-213
Full Text |
Full-Text PDF (49 KB)
|
|
Efficacy and Safety of Fixed-Dose Rosuvastatin/Fenofibric Acid Versus Simvastatin Monotherapy in Patients with Elevated Low-Density Lipoprotein Cholesterol and Triglycerides
Eli M. Roth, James M. McKenney, Maureen T. Kelly, Carolyn M. Setze, Dawn M. Carlson, Alex Gold, Michael Cressman, James C. Stolzenbach, Laura A. Williams, Peter H. Jones
page 213
Full Text |
Full-Text PDF (38 KB)
|
|
Aspirin Reduces Transient Flushing and Glucose Increases During Therapy with Niacin Extended-Release
Robert J. Padley, Roopal B. Thakkar, Ping Jiang, Scott L. Krause, Michael H. Davidson, Henry A. Punzi
pages 213-214
Full Text |
Full-Text PDF (99 KB)
|
|
Aspirin Improves Niacin-Associated Flushing and its Impact on Dyslipidemic Patients' Quality of Life
Thao T. Dong, Ping Jiang, Rhea Parreno, Roopal B. Thakkar, Scott L. Krause, Robert J. Padley
page 214
Full Text |
Full-Text PDF (90 KB)
|
|
Sex and Ethnic Disparities in High-Density Lipoprotein Subclasses∗
Palaniappan Manickam, Ankit Rathod, Praveen Guntipalli, Pawan Hari, Vikas Veeranna, Sony Jacob, Luis Afonso
pages 214-215
Full Text |
Full-Text PDF (100 KB)
|
|
The Lipid-Altering Effects of Extended-Release Niacin/Laropiprant Among Different Patient Subgroups
Harold Edward Bays, Alexandra MacLean, Arvind Shah, Christine McCrary Sisk, Qian Dong, Darbie Maccubbin
page 215
Full Text |
Full-Text PDF (38 KB)
|
|
Effect of Hepatic Impairment on the Pharmacokinetics of Dalcetrapib
Mary Phelan, Olaf Kuhlmann, Judith Anzures-Cabrera, Bimaljit Matharu, Darren Bentley
pages 215-216
Full Text |
Full-Text PDF (50 KB)
|
|
No Clinically Relevant Drug-Drug Interactions Between Dalcetrapib and a Monophasic Oral Contraceptive (Microgynon-30®)
Anne-Marie Young, Adam Foley-Comer, Judith Anzures-Cabrera, Michael Derks
page 216
Full Text |
Full-Text PDF (41 KB)
|
|
Prognostic Factors that Influence the Risk of Intensification of Anti-Hyperglycemic Medication Among Patients with Type 2 Diabetes
Darbie Maccubbin, Alexandra MacLean, Hilde Giezek, Christine McCray Sisk
page 216
Full Text |
Full-Text PDF (41 KB)
|
|
Extended-Release Nicotinic Acid Versus Inositol Hexanicotinate for the Treatment of Dyslipidemia
Joseph Keenan
pages 216-217
Full Text |
Full-Text PDF (51 KB)
|
|
Prognostic Utility of Lipid Parameters in Prediction of New-Onset Microalbuminuria in Hypertensive Patients∗
Palaniappan Manickam, Praveen Guntipalli, Ankit Rathod, Pawan Kumar Hari, Rajeev Sudhaker, Vikas Veerenna, Sony Jacob, Luis Afonso
page 217
Full Text |
Full-Text PDF (38 KB)
|
|
Acute Reduction of Lipoprotein (a) After Low-Density Lipoprotein Apheresis May Improve Symptoms of Angina∗
Deepti Bulchandani, Patrick Moriarty
pages 217-218
Full Text |
Full-Text PDF (50 KB)
|
|
Predictors of Combination Therapy for the Treatment of Dyslipidemia in the Actual Clinical Practice-Setting
Radhika Nair, Woodie Zachry
page 218
Full Text |
Full-Text PDF (39 KB)
|
|
The Treatment of Dyslipidemia in Actual Practice Settings That Use Similar Inclusion Criteria to the ACCORD Lipid Trial
Radhika Nair, Woodie Zachry
pages 218-219
Full Text |
Full-Text PDF (50 KB)
|
|
Associations Between Switches to Simvastatin and Low-Density Lipoprotein Goal Attainment Among High-Risk Patients in a US Managed-Care Population
David Robert Neff, Kaan Tunceli, Shiva Sajjan, Dena Ramey, Andrew M. Tershakovec, Henry X. Hu, JoAnne M. Foody
page 219
Full Text |
Full-Text PDF (39 KB)
|
|
Changes in Prescription Patterns for Ezetimibe/Simvastatin, Ezetimibe and Statin, and Statin Therapies and Expected Effects on LDL-C Reduction
Peter Paul Toth, Christie M. Ballantyne, Michael H. Davidson, Dena Ramey, David Neff, Andrew M. Tershakovec, Henry X. Hu, Joanne E. Tomassini, Kaan Tunceli
pages 219-220
Full Text |
Full-Text PDF (51 KB)
|
|
Colesevelam HCl to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study
Sam Misir, Yehuda Handelsman, Timothy W. Garvey, Vivian A. Fonseca, Julio Rosenstock, Michael R. Jones, Yu-Ling Lai, Xiaoping Jin, Sukumar Nagendran, Stacey L. Abby
page 220
Full Text |
Full-Text PDF (40 KB)
|
|
Mipomersen, a First-in-Class Apolipoprotein B Synthesis Inhibitor, Lowers Lipoprotein (a) in Patients with Homozygous Familial Hypercholesterolemia
William C. Cromwell, Raul D. Santos, Dirk J. Blom, David A. Marais, Robin H. Lachmann, Daniel Gaudet, Ju L. Tan, Scott Chasan-Taber, Diane L. Tribble, JoAnn Flaim, Frederick J. Raal, Min-Ji Charng
page 221
Full Text |
Full-Text PDF (39 KB)
|
|
|
|
|
|
|
|
